Madrigal Pharmaceuticals
MDGL
387 hedge funds and large institutions have $13.7B invested in Madrigal Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 137 increasing their positions, 113 reducing their positions, and 41 closing their positions.
107% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 41
28% more capital invested
Capital invested by funds: $10.7B → $13.7B (+$2.99B)
21% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 113
19% more call options, than puts
Call options by funds: $323M | Put options by funds: $271M
10% more funds holding
Funds holding: 352 → 387 (+35)
1.57% less ownership
Funds ownership: 105.34% → 103.78% (-1.6%)
7% less funds holding in top 10
Funds holding in top 10: 14 → 13 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$87.7M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$79M |
| 3 |
AC
Armistice Capital
New York
|
+$74.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$72.9M |
| 5 |
Alkeon Capital Management
New York
|
+$61.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$132M |
| 2 |
PC
Paulson & Co
New York
|
-$102M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$58.6M |
| 4 |
Morgan Stanley
New York
|
-$50.7M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$42.8M |
MDGL Hedge Fund Activity: Q4 2025 in Review
387 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2025, worth a combined $13.7B — up 28% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new MDGL positions and 41 closed out — a net gain of 44 holders — while 137 added to existing stakes and 113 trimmed.
The largest buyer was Bank of America, adding an estimated $87.7M. The largest seller was Janus Henderson Group, cutting an estimated $132M.
- 387 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2025, up from 352 in Q3 2025.
- Funds reported $13.7B of Madrigal Pharmaceuticals stock for Q4 2025, up 28% quarter-over-quarter.
- 85 funds opened new Madrigal Pharmaceuticals positions in Q4 2025 and 41 closed out, a net change of +44 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2025 was Bank of America, an estimated $87.7M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2025 was Janus Henderson Group, an estimated $132M sold.
Based on aggregated 13F filings for Q4 2025.